Evidence map›Paper›PMID 26977880›Full record

ArticleCancer cell2016

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

Haidong Tang, Yang Wang, Lukasz K Chlewicki, Yuan Zhang, Jingya Guo, Wei Liang, Jieyi Wang, Xiaoxiao Wang, Yang-Xin Fu

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 225 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 2 pooled it
23.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 2 syntheses or guidelines pooled it, 482 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Linking tumour angiogenesis and tumour immunity.Nature reviews. Immunology · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Haidong TangDepartment of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Yang WangDepartment of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Lukasz K ChlewickiDepartment of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
Yuan ZhangDepartment of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
Jingya GuoChinese Academy of Science Key Laboratory for Infection and Immunity, IBP-UTSW Joint Immunotherapy Group, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Wei LiangChinese Academy of Science Key Laboratory for Infection and Immunity, IBP-UTSW Joint Immunotherapy Group, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Jieyi WangOncology Biologics, AbbVie Biotherapeutics Research (ABR), 1500 Seaport Boulevard, Redwood City, CA 94063, USA.
Xiaoxiao WangAlphamab Co. Ltd., Suzhou, Jiangsu 215125, China.
Yang-Xin FuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA; Chinese Academy of Science Key Laboratory for Infection and Immunity, IBP-UTSW Joint Immunotherapy Group, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: yang-xin.fu@utsouthwestern.edu.
University of Chicago · USChinese Academy of Sciences · CNAbbVie (United States) · USAlibaba Group (China) · CN

Funding

Synergy of Radiation and Immunotherapy: New ApproachesR01CA134563 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MALTER, JAMES S · 2010 to 2019
$3.4M
TNF family members for lymph angiogenesis and lymph node hypertrophyR01CA141975 · NCI · UNIVERSITY OF CHICAGO · PI FU, YANG-XIN · 2010 to 2014
$1.6M
NCI NIH HHS CA141975NCI NIH HHS R01 CA134563NCI NIH HHS R01 CA141975
6 · The paper itself

Abstract

Immune checkpoint blockade therapies fail to induce responses in the majority of cancer patients, so how to increase the objective response rate becomes an urgent challenge. Here, we demonstrate that sufficient T cell infiltration in tumor tissues is a prerequisite for response to PD-L1 blockade. Targeting tumors with tumor necrosis factor superfamily member LIGHT activates lymphotoxin β-receptor signaling, leading to the production of chemokines that recruit massive numbers of T cells. Furthermore, targeting non-T cell-inflamed tumor tissues by antibody-guided LIGHT creates a T cell-inflamed microenvironment and overcomes tumor resistance to checkpoint blockade. Our data indicate that targeting LIGHT might be a potent strategy to increase the responses to checkpoint blockades and other immunotherapies in non-T cell-inflamed tumors.

Indexed as

Amino Acid SequenceAnimalsAntineoplastic AgentsB7-H1 AntigenDrug Resistance, NeoplasmHumansImmunotherapyLymphotoxin beta ReceptorMiceMice, Inbred C57BLSignal TransductionT-LymphocytesTumor MicroenvironmentTumor Necrosis Factor-alphaAntineoplastic AgentsB7-H1 AntigenLymphotoxin beta ReceptorTumor Necrosis Factor-alpha

Identifiers

PMID26977880
PMCPMC4794755
OpenAlexW2294356527

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.